Cautious Optimism: Amgen’s Uplizna Shows Promise but Limited Immediate Impact on Valuation
Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Amgen (AMGN – Research Report), retaining the price target of $335.00.
Zacks.com on MSN22d
AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's Why
Shares of Amgen AMGN fell by more than 5% on Wednesday after it reported top-line data on two different drugs in the ...
FiercePharma23d
With success in myasthenia gravis trial, Amgen's Uplizna looks set up to add new indication
Uplizna was one of the key drugs acquired from the company’s $27.8 billion acquisition of Horizon Therapeutics, which was completed in October of last year. Amgen Uplizna Myasthenia Gravis ...
Investing2d
Amgen's UPLIZNA shows promise in myasthenia gravis trial
THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN) has revealed positive results from its Phase 3 MINT trial for UPLIZNA (inebilizumab-cdon), a treatment for adults with generalized myasthenia gravis (gMG) ...